Louis Lange
QuietNamed in filings at Asset Management VenturesOn the current fund
- Board seats filed
- 4
Named in filings at Asset Management VenturesOn the current fund
all filings on record
last 24 months
from a verified or cited source
| Audentes Therapeutics | Biotech & pharma | August 2015 | 270 Healthcare Growth, Caduceus Capital, Orbimed Genesis, Versant Venture Capital |
| Amygdala Neurosciences | Biotech & pharma | April 2015 | None on file |
| Cardiogen Sciences | Not yet classified | November 2014 | None on file |
| CARDIODX | Biotech & pharma | July 2014 | Longitude Capital |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The sector is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Classified sectors of companies where filings name Louis Lange on the board, based on 3 filed seats with a verified or cited source.
1 more filed seat not yet classified, left out of the shares above.